Newsroom | 61841 results

TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced the voting results from its Annual General and Special Meeting of Shareholders (the “Meeting”) held on June 11, 2025 and the grant of stock options (“Options”) and restricted share units (“RSUs”). All figures are in Canadian dollars, unless otherwise noted. The results of the director elections wer...

HOUSTON--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, today announced that Chris Reading, Chief Executive Officer, presented at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025, and Carey Hendrickson, Chief Financial Officer, presented at the 15th Annual East Coast IDEAS Conference on June 11, 2025. The presentations provided an overview of t...

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Conference, taking place June 16-17, 2025. Mr. Drysdale’...

LONDON--(BUSINESS WIRE)--MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, announced today that it will present new pre-clinical data on its RNA activation program for the treatment of sickle cell disease at the European Hematology Association 2025 Congress. Pre-clinical studies of MTL-HBG drug candidate demonstrated best-in-class activity in a highly translatable model and underscore its transformational therapeutic potential in sickle cell disease. The data w...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, immunogenicity and efficacy of a single dose of V181, an investigational quadrivalent vaccine, for the prevention of dengue disease caused by any of the four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), regardless of prior dengue exposure. Recruitment for the trial has begun, and the...

LONDON--(BUSINESS WIRE)--Galderma today announced that nemolizumab has been recommended for routine funding on the National Health Service in England and Wales for moderate-to-severe atopic dermatitis in final draft guidance from the National Institute for Health and Care Excellence.1 This follows its recent marketing authorisation by the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency for the treatment of moderate-to-severe atopic dermatitis in combination with topical...

BAAR, Suisse--(BUSINESS WIRE)--Stallergenes Greer, un leader mondial dans le traitement des allergies, présentera ses dernières avancées scientifiques lors du congrès 2025 de l’Académie européenne d’allergologie et d’immunologie clinique (EAACI), qui se tient à Glasgow (Royaume-Uni) du 13 au 16 juin. Stallergenes Greer présentera également 25 posters et parrainera deux symposiums scientifiques au cours desquels six experts de renommée mondiale partageront leur expertise des allergies respiratoi...

BAAR, Switzerland--(BUSINESS WIRE)--Stallergenes Greer showcases developments in respiratory and food allergy care at EAACI 2025...

NEW DELHI, Inde--(BUSINESS WIRE)--Advantage Healthcare India 2025, un sommet international consacré à la promotion de la position de l’Inde en tant que plaque tournante mondiale du tourisme de santé, a reconnu la contribution mondiale de Fortis Healthcare à ce type de tourisme. Fortis a en effet contribué à la réputation de l’Inde en tant que destination de premier choix pour le tourisme de santé. Fortis Healthcare a remporté des prix « Medical Value Travel Awards 2025 » décernés par Advantage...